| R&D Reference Number | Project Short title | Project Full title | Recruitment end date |
| 1804569 | Predictors of depression in people with Ulcerative Colitis – Version 1 | Prospective cohort study to identify causes of depression and how depression leads to relapse in people with ulcerative colitis | 01/08/2018 |
| 1609306 | GAST 5438 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy | 11/08/2018 |
| 1507119 | Study of Immune Drug Side Effects-SIDEFX. Version 1.0 | 01/09/2018 | |
| 1707456 | Efficacy and Safety of Fligotinib in Active Crohn’s Disease | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Fligotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease | 30/09/2018 |
| 1807651 | GS-US-419-4015 Filgotinib in treatment of Small Bowel Crohn’s Disease | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) | 23/10/2018 |
| 906278 | IBD-GEN | Characterising the Genetic Determinants of Inflammatory Bowel Disease | 10/11/2018 |
| 1711527 | GS-US-419 4016 Filgotinib in treatment of Perianal Fistulizing Crohns | A Phase 2, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of Filgotinib in the treatment of Perianal Fistulizing Crohn’s Disease. | 30/11/2018 |
| 1607279 | SPARE | A proSpective randomized controlled trial comParing infliximAbantimetabolites combination therapy to antimetabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy (SPARE) | 31/12/2018 |
| 1609302 | I-CARE – IBD Cancer and Serious Infections in Europe | I-CARE – IBD Cancer and Serious Infections in Europe | 31/12/2018 |
| 1802586 | Biomarkers of malignancy from pancreatic cysts | Molecular biomarkers in pancreatic cyst fluid to improve diagnostic accuracy and malignancy risk assessment. | 31/03/2019 |
| 1511174 | GAST 4652 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | 01/04/2019 |
| 1808667 | Testicular Safety of Filgotinib in Males with Ulcerative Colitis | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis | 30/04/2019 |
| 1508131 | GAST 3772 | Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study To Evaluate The Efficacy And Safety Of Etrolizumab Compared With Infliximab In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Naive To TNF Inhibitors | 09/05/2019 |
| 1307805 | PANTS | Personalised Anti-TNF in Crohns Disease | 02/06/2019 |
| 1708486 | Long Term Safety of Filgotinib in Active Crohn’s Disease | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease | 30/11/2019 |
| 1206654 | PRED 4 – Predicting Serious Drug Side Effects in Gastroenterology | PRED 4 – Predicting Serious Drug Side Effects in Gastroenterology | 31/12/2019 |
| 1712550 | PROFILE – personalised medicine in Crohn’s disease | PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE) trial | 28/02/2020 |
| 1708482 | M14-533 Ph 3 study in Mod/Severe Ulcerative Colitis Extension study | A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC) | 20/04/2020 |
| 1708483 | M14-234 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | 28/04/2020 |
| 1608299 | IBD Bioresource | The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn’s Disease & Ulcerative Colitis | 01/10/2020 |
| 1609307 | GAST 5440 | A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease | 30/06/2021 |
| 1607270 | GAST 4844 | A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | 30/09/2021 |
| 1511175 | GAST 4684 | AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLEDIN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 | 02/07/2022 |
| 1511170 | GAST 3773 | An Open-Label Extension And Safety Monitoring Study Of Moderate To Severe Ulcerative Colitis Patients Previously Enrolled In Etrolizumab Phase III Studies | 13/03/2024 |
